Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2011

Open Access 01-12-2011 | Original investigation

Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria

Authors: Henrik Reinhard, Mads Nybo, Peter R Hansen, Niels Wiinberg, Andreas Kjær, Claus L Petersen, Kaj Winther, Hans-Henrik Parving, Lars M Rasmussen, Peter Rossing, Peter K Jacobsen

Published in: Cardiovascular Diabetology | Issue 1/2011

Login to get access

Abstract

Objective

Plasma osteoprotegerin (P-OPG) is an independent predictor of cardiovascular disease in diabetic and other populations. OPG is a bone-related glycopeptide produced by vascular smooth muscle cells and increased P-OPG may reflect arterial damage. We investigated the correlation between P-OPG and coronary artery disease (CAD) in asymptomatic type 2 diabetic patients with microalbuminuria.

Methods

P-OPG was measured in 200 asymptomatic diabetic patients without known cardiac disease. Patients with P-NT-proBNP >45.2 ng/l and/or coronary calcium score (CCS) ≥400 were stratified as high risk of CAD (n = 133), and all other patients as low risk patients (n = 67). High risk patients were examined by myocardial perfusion imaging (MPI; n = 109), and/or CT-angiography (n = 20), and/or coronary angiography (CAG; n = 86). Significant CAD was defined by presence of significant myocardial perfusion defects at MPI and/or >70% coronary artery stenosis at CAG.

Results

Significant CAD was demonstrated in 70 of the high risk patients and of these 23 patients had >70% coronary artery stenosis at CAG. Among high risk patients, increased P-OPG was an independent predictor of significant CAD (adjusted odds ratio [CI] 3.11 [1.01-19.54] and 3.03 [1.00-9.18] for second and third tertile vs.first tertile P-OPG, respectively) and remained so after adjustments for NT-proBNP and CCS. High P-OPG was also associated with presence of >70% coronary artery stenosis(adjusted odds ratio 14.20 [1.35-148.92] for third vs. first tertile P-OPG), and 91% of patients with low (first tertile) P-OPG did not have >70% coronary artery stenosis.

Conclusions

Elevated P-OPG is an independent predictor of the presence of CAD in asymptomatic type 2 diabetic patients with microalbuminuria.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, MacMahon S, Chalmers J: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009, 20: 1813-1821. 10.1681/ASN.2008121270.PubMedCentralCrossRefPubMed Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, MacMahon S, Chalmers J: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009, 20: 1813-1821. 10.1681/ASN.2008121270.PubMedCentralCrossRefPubMed
2.
go back to reference Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM: Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia. 2008, 51: 2100-2107. 10.1007/s00125-008-1123-8.CrossRefPubMed Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM: Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia. 2008, 51: 2100-2107. 10.1007/s00125-008-1123-8.CrossRefPubMed
3.
go back to reference Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, Rossing P: Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care. 2010, 33: 2561-2566. 10.2337/dc10-0858.PubMedCentralCrossRefPubMed Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, Rossing P: Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care. 2010, 33: 2561-2566. 10.2337/dc10-0858.PubMedCentralCrossRefPubMed
4.
go back to reference Anand DV, Lahiri A, Lim E, Hopkins D, Corder R: The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006, 47: 1850-1857. 10.1016/j.jacc.2005.12.054.CrossRefPubMed Anand DV, Lahiri A, Lim E, Hopkins D, Corder R: The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006, 47: 1850-1857. 10.1016/j.jacc.2005.12.054.CrossRefPubMed
5.
go back to reference Nybo M, Rasmussen LM: The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol. 2008, 159: 603-608. 10.1530/EJE-08-0554.CrossRefPubMed Nybo M, Rasmussen LM: The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol. 2008, 159: 603-608. 10.1530/EJE-08-0554.CrossRefPubMed
6.
go back to reference Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997, 89: 309-319. 10.1016/S0092-8674(00)80209-3.CrossRefPubMed Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997, 89: 309-319. 10.1016/S0092-8674(00)80209-3.CrossRefPubMed
7.
go back to reference Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998, 273: 14363-14367. 10.1074/jbc.273.23.14363.CrossRefPubMed Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998, 273: 14363-14367. 10.1074/jbc.273.23.14363.CrossRefPubMed
8.
go back to reference Olesen P, Ledet T, Rasmussen LM: Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia. 2005, 48: 561-568. 10.1007/s00125-004-1652-8.CrossRefPubMed Olesen P, Ledet T, Rasmussen LM: Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia. 2005, 48: 561-568. 10.1007/s00125-004-1652-8.CrossRefPubMed
9.
go back to reference Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y: Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002, 106: 1192-1194. 10.1161/01.CIR.0000031524.49139.29.CrossRefPubMed Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y: Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002, 106: 1192-1194. 10.1161/01.CIR.0000031524.49139.29.CrossRefPubMed
10.
go back to reference Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004, 109: 2175-2180. 10.1161/01.CIR.0000127957.43874.BB.CrossRefPubMed Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004, 109: 2175-2180. 10.1161/01.CIR.0000127957.43874.BB.CrossRefPubMed
11.
go back to reference Browner WS, Lui LY, Cummings SR: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001, 86: 631-637. 10.1210/jc.86.2.631.PubMed Browner WS, Lui LY, Cummings SR: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001, 86: 631-637. 10.1210/jc.86.2.631.PubMed
12.
go back to reference Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008, 358: 580-591. 10.1056/NEJMoa0706245.CrossRefPubMed Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008, 358: 580-591. 10.1056/NEJMoa0706245.CrossRefPubMed
13.
go back to reference Reinhard H, Hansen PR, Persson F, Tarnow L, Wiinberg N, Kjaer A, Petersen CL, Winther K, Parving HH, Rossing P, Jacobsen PK: Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant. 2011 Reinhard H, Hansen PR, Persson F, Tarnow L, Wiinberg N, Kjaer A, Petersen CL, Winther K, Parving HH, Rossing P, Jacobsen PK: Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant. 2011
14.
go back to reference Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH: Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia. 2006, 49: 2256-2262. 10.1007/s00125-006-0359-4.CrossRefPubMed Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH: Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia. 2006, 49: 2256-2262. 10.1007/s00125-006-0359-4.CrossRefPubMed
15.
go back to reference Lassen NA, Tvedegaard E, Jeppesen FI, Nielsen PE, Bell G, Gundersen J: Distal blood pressure measurement in occlusive arterial disease, strain gauge compared to xenon-133. Angiology. 1972, 23: 211-217. 10.1177/000331977202300405.CrossRefPubMed Lassen NA, Tvedegaard E, Jeppesen FI, Nielsen PE, Bell G, Gundersen J: Distal blood pressure measurement in occlusive arterial disease, strain gauge compared to xenon-133. Angiology. 1972, 23: 211-217. 10.1177/000331977202300405.CrossRefPubMed
16.
go back to reference Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990, 15: 827-832. 10.1016/0735-1097(90)90282-T.CrossRefPubMed Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990, 15: 827-832. 10.1016/0735-1097(90)90282-T.CrossRefPubMed
17.
go back to reference Chiu YW, Adler SG, Budoff MJ, Takasu J, Ashai J, Mehrotra R: Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int. 2010, 77: 1107-1114. 10.1038/ki.2010.70.CrossRefPubMed Chiu YW, Adler SG, Budoff MJ, Takasu J, Ashai J, Mehrotra R: Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int. 2010, 77: 1107-1114. 10.1038/ki.2010.70.CrossRefPubMed
18.
go back to reference Abbara S, Arbab-Zadeh A, Callister TQ, Desai MY, Mamuya W, Thomson L, Weigold WG: SCCT guidelines for performance of coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr. 2009, 3: 190-204. 10.1016/j.jcct.2009.03.004.CrossRefPubMed Abbara S, Arbab-Zadeh A, Callister TQ, Desai MY, Mamuya W, Thomson L, Weigold WG: SCCT guidelines for performance of coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr. 2009, 3: 190-204. 10.1016/j.jcct.2009.03.004.CrossRefPubMed
19.
go back to reference Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM: Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003, 149: 39-42. 10.1530/eje.0.1490039.CrossRefPubMed Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM: Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003, 149: 39-42. 10.1530/eje.0.1490039.CrossRefPubMed
20.
go back to reference Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ: Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001, 21: 1998-2003. 10.1161/hq1201.100229.CrossRefPubMed Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ: Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001, 21: 1998-2003. 10.1161/hq1201.100229.CrossRefPubMed
21.
go back to reference Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM: Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care. 2005, 28: 2176-2180. 10.2337/diacare.28.9.2176.CrossRefPubMed Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM: Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care. 2005, 28: 2176-2180. 10.2337/diacare.28.9.2176.CrossRefPubMed
22.
go back to reference Ito H, Komatsu Y, Mifune M, Antoku S, Ishida H, Takeuchi Y, Togane M: The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2010, 9: 18-10.1186/1475-2840-9-18.PubMedCentralCrossRefPubMed Ito H, Komatsu Y, Mifune M, Antoku S, Ishida H, Takeuchi Y, Togane M: The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2010, 9: 18-10.1186/1475-2840-9-18.PubMedCentralCrossRefPubMed
23.
go back to reference Di AE, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J: B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation. 2009, 120: 2177-2187. 10.1161/CIRCULATIONAHA.109.884866.CrossRef Di AE, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J: B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation. 2009, 120: 2177-2187. 10.1161/CIRCULATIONAHA.109.884866.CrossRef
24.
go back to reference Oudkerk M, Stillman AE, Halliburton SS, Kalender WA, Mohlenkamp S, McCollough CH, Vliegenthart R, Shaw LJ, Stanford W, Taylor AJ, van Ooijen PM, Wexler L, Raggi P: Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. Int J Cardiovasc Imaging. 2008, 24: 645-671. 10.1007/s10554-008-9319-z.PubMedCentralCrossRefPubMed Oudkerk M, Stillman AE, Halliburton SS, Kalender WA, Mohlenkamp S, McCollough CH, Vliegenthart R, Shaw LJ, Stanford W, Taylor AJ, van Ooijen PM, Wexler L, Raggi P: Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. Int J Cardiovasc Imaging. 2008, 24: 645-671. 10.1007/s10554-008-9319-z.PubMedCentralCrossRefPubMed
25.
go back to reference Shaw LJ, Polk DM, Kahute TA, Wong ND, Moon J, Miranda-Peats R, Rozanski A, Friedman JD, Hayes S, Thomson L, Berman DS: Prognostic accuracy of B-natriuretic peptide measurements and coronary artery calcium in asymptomatic subjects (from the Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research [EISNER] study). Am J Cardiol. 2009, 104: 1245-1250. 10.1016/j.amjcard.2009.06.041.CrossRefPubMed Shaw LJ, Polk DM, Kahute TA, Wong ND, Moon J, Miranda-Peats R, Rozanski A, Friedman JD, Hayes S, Thomson L, Berman DS: Prognostic accuracy of B-natriuretic peptide measurements and coronary artery calcium in asymptomatic subjects (from the Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research [EISNER] study). Am J Cardiol. 2009, 104: 1245-1250. 10.1016/j.amjcard.2009.06.041.CrossRefPubMed
26.
go back to reference Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, Rupprecht HJ, Bickel C, Tiret L, Cambien F, Gerstein H, Munzel T, Yusuf S: Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006, 114: 201-208. 10.1161/CIRCULATIONAHA.105.590927.CrossRefPubMed Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, Rupprecht HJ, Bickel C, Tiret L, Cambien F, Gerstein H, Munzel T, Yusuf S: Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006, 114: 201-208. 10.1161/CIRCULATIONAHA.105.590927.CrossRefPubMed
27.
go back to reference Folsom AR, Kronmal RA, Detrano RC, O'Leary DH, Bild DE, Bluemke DA, Budoff MJ, Liu K, Shea S, Szklo M, Tracy RP, Watson KE, Burke GL: Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2008, 168: 1333-1339. 10.1001/archinte.168.12.1333.PubMedCentralCrossRefPubMed Folsom AR, Kronmal RA, Detrano RC, O'Leary DH, Bild DE, Bluemke DA, Budoff MJ, Liu K, Shea S, Szklo M, Tracy RP, Watson KE, Burke GL: Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2008, 168: 1333-1339. 10.1001/archinte.168.12.1333.PubMedCentralCrossRefPubMed
28.
go back to reference Stepien E, Wypasek E, Stopyra K, Konieczynska M, Przybylo M, Pasowicz M: Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin Biochem. 2011, 44: 826-831. 10.1016/j.clinbiochem.2011.04.016.CrossRefPubMed Stepien E, Wypasek E, Stopyra K, Konieczynska M, Przybylo M, Pasowicz M: Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin Biochem. 2011, 44: 826-831. 10.1016/j.clinbiochem.2011.04.016.CrossRefPubMed
29.
go back to reference Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR: Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol. 2005, 204: 714-723. 10.1002/jcp.20354.CrossRefPubMed Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR: Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol. 2005, 204: 714-723. 10.1002/jcp.20354.CrossRefPubMed
30.
go back to reference Nellemann B, Gormsen LC, Dollerup J, Schmitz O, Mogensen CE, Rasmussen LM, Nielsen S: Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care. 2007, 30: 3122-3124. 10.2337/dc07-0919.CrossRefPubMed Nellemann B, Gormsen LC, Dollerup J, Schmitz O, Mogensen CE, Rasmussen LM, Nielsen S: Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care. 2007, 30: 3122-3124. 10.2337/dc07-0919.CrossRefPubMed
31.
go back to reference Park JS, Cho MH, Nam JS, Yoo JS, Ahn CW, Cha BS, Kim KR, Lee HC: Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2011, 164: 69-74. 10.1530/EJE-10-0875.PubMedCentralCrossRefPubMed Park JS, Cho MH, Nam JS, Yoo JS, Ahn CW, Cha BS, Kim KR, Lee HC: Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2011, 164: 69-74. 10.1530/EJE-10-0875.PubMedCentralCrossRefPubMed
32.
go back to reference Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009, 360: 2503-2515.CrossRefPubMed Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009, 360: 2503-2515.CrossRefPubMed
Metadata
Title
Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria
Authors
Henrik Reinhard
Mads Nybo
Peter R Hansen
Niels Wiinberg
Andreas Kjær
Claus L Petersen
Kaj Winther
Hans-Henrik Parving
Lars M Rasmussen
Peter Rossing
Peter K Jacobsen
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2011
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-10-70

Other articles of this Issue 1/2011

Cardiovascular Diabetology 1/2011 Go to the issue